Scientific Articles

The final decades of the 20th century radically changed the concept of the pathogenesis of H. pylori-associated gastric diseases—chronic gastritis (CG) type B and duodenal ulcer (DU)—and their treatment, through the introduction of potent antisecretory drugs and eradication therapy (ET) for Helicobacter pylori (HP) infection [1, 2]. Most likely, the near future will bring further development of the most successful therapeutic methods proposed in the 20th century [3, 4].

Peptic ulcer disease is a chronic relapsing disease of the gastroduodenal area, the main manifestation of which is the formation of ulcers on the gastric or duodenal mucosa, which in most cases develop against a background of chronic gastritis caused by Helicobacter pylori (H. pylori) infection.

The article discusses the prevention and treatment of intestinal dysbiosis associated with antibiotic therapy. It provides a brief overview of probiotics, prebiotics, and synbiotics. To prevent complications, drugs that stimulate the growth of normal intestinal microflora should be prescribed alongside antibiotics.

The results of our own study on the use of Ekozitrin (clarithromycin + lactulose) in the therapy of chronic urogenital chlamydia in 32 patients who had previously received antibiotic therapy for chlamydia with insufficient effect are presented.